Lanadelumab for prevention of attacks of non-histaminergic normal C1 inhibitor angioedema: results from the randomized, double-blind CASPIAN Study and CASPIAN open-label extension

ABSTRACT:

SUBMITTER: Riedl M 

PROVIDER: S-EPMC12135624 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature